Targeting unmet needs in personalized oncology

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers in order to produce innovative diagnostic kits for cancer early detection, monitoring, and evaluation of response to therapy. By exploiting the natural immune response to early stage cancer and the proprietary platform technology Combinatorial Proteomic®, XEPTAGEN has discovered predictive, prognostic and early response tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. Our mission includes creating innovative tools that improve the clinical management of cancer patients.

Press Releases

SCCA-IgM in nonalcoholic steatohepatitis (NASH)

Funds from POR CRO FESR 2007-2013 Action 5.1.1 2/2013 granted to Xeptagen S.P.A. by Regione Veneto.

Prospective study on SCCA-IgM as predictor of HCC development in HCV+ cirrhotic patients presented at the 47th AISF Meeting.

Method to improve the diagnostic accuracy of PSA-IgM published in Cancer Biomarkers.

AIGO results on CEA-IgM presented at 18° FISMAD congress.

iXip - index for Prostate Cancer

Novel Index for
Prostate Cancer

HepaIC - Assessment of the risk of HCC development in cirrhosis

Assessment of the risk of HCC development in cirrhosis


Xeptagen SpA. - P.iva: 07784560638 - Copyright © 2013. All rights reserved. For any problems, please contact


Forgot your password?